Molecular Templates, Inc.


Promising Therapy for HER2 Cancer Patients

MT-5111 is a second generation engineered toxin body (ETB) consisting of a single-chain variable fragment (scFv) with an affinity for HER2, fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA). MT-5111 specifically binds and kills HER2 expressing cells in a manner consistent with SLTA mediated cellular cytotoxicity.

MT-5111 is designed to avoid competition with and to overcome the primary mechanisms of tumor resistance to current HER2 targeted therapies. MT-5111 may provide benefits to patients with HER2-positive cancers by potentially overcoming mechanisms of tumor resistance to existing HER2 targeted therapies.

Program Partner Indication (Target) Preclinical Phase 1 Phase 2 Phase 3 Next Stage
MT-5111 Multiple - solid tumors (HER2)
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started
a) Potential for Phase 2 to be pivotal in relapsed/refractory setting as monotherapy
Phase 2 is potentially pivotal

Potential Benefits

Designed to Overcome Resistance Mechanisms

  • MT-5111 has a wholly unique mechanism of action that does not appear subject to the resistant mechanism associated with Mabs, TKIs, or ADCs.
  • MT-5111 binds in the presence of trastuzumab, pertuzumab or T-DM1, has picomolar efficacy, and is active in T-DM1 refractory cells.

Clinical Overview

The Phase 1 study in patients with HER2 positive solid tumors began dosing in the fourth quarter of 2019 and we anticipate reporting updates on the study in 2020.

View Clinical Trials
Posters & Presentations

Posters & Presentations

To learn more about the MT-5111 candidate, explore our research publications.

View Posters & Presentations